Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells.
about
Exosomes as a tumor immune escape mechanism: possible therapeutic implicationsSerological detection of cutaneous T-cell lymphoma-associated antigensAdvances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerDendritic cell-based cancer immunotherapy for colorectal cancerUse of Cell-Penetrating Peptides in Dendritic Cell-Based VaccinationPathways and therapeutic targets in melanomaCancer immunotherapy via dendritic cellsCombining cytotoxic and immune-mediated gene therapy to treat brain tumorsA novel, rapid strategy to form dendritomas from human dendritic cells and hepatocellular carcinoma cell line HCCLM3 cells using mature dendritic cells derived from human peripheral blood CD14+ monocytes within 48 hours of in vitro culture.Selected climatic variables and blood pressure in Central European patients with chronic renal failure on haemodialysis treatment.Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responsesGlioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.Progress in active-specific immunotherapy of brain malignancies.Dendritic cells for specific cancer immunotherapy.Dendritic cell vaccination for cancer therapy.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer.DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patientsDendritic cell-based vaccines and therapies for cancer.The Type III secretion system of Gram-negative bacteria: a potential therapeutic target?Current immunotherapeutic approaches in pancreatic cancer.Peptide-based vaccines for cancer immunotherapy.Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells.Immunotherapy for gynaecological malignancies.Uric acid enhances the antitumor immunity of dendritic cell-based vaccineTrial watch: Dendritic cell-based interventions for cancer therapyExpansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells.Immune cell recruitment and cell-based system for cancer therapy.UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumourWhat is recent in pancreatic cancer immunotherapy?Immunotherapy opportunities in ovarian cancer.Toward effective immunotherapy for the treatment of malignant brain tumorsIs cancer gene therapy an empty suit?The immunotherapeutic potential of dendritic cells in type 1 diabetes.Cancer immunotherapy by fusions of dendritic cells and tumor cells.The biology of cancer testis antigens: putative function, regulation and therapeutic potential
P2860
Q21245472-FD73F815-F3F4-42E2-BACE-D0FEFEA61DEAQ24544114-40962DFF-05B1-4E80-8914-BBCDED985071Q26749451-6D78658E-D4E8-49AE-A35E-2917C8391B7FQ26751339-55453704-9FD5-4CE1-B2CD-A4C56240DB8CQ26764861-F27795F4-078D-4F42-AA2A-5350154B9058Q26865736-9155ED36-B02D-4CAE-B32C-3B8C3393A437Q29615444-E258AE33-57B3-4B23-9A1C-DE51D50603A4Q31013320-9BD1998F-5D91-45EC-87D6-ECBB740F2ACDQ33208820-BC081BD0-927C-4C35-91C2-EE1369506802Q33433723-0D413139-356C-4F7C-965D-5A1BEBA1E992Q33643966-EDF0ECF8-418B-4F89-B579-328BCBF20C8CQ33999299-0F1385E6-D866-4D3F-8F7E-F8B86C646FF3Q34063140-191145EC-2118-4C80-8EB2-C14F177C00C1Q34075068-5E25E272-5596-4883-B8E0-18E6E9DC0534Q34280913-C0B1F97E-0C2B-44FF-8DF0-26AA5AD40A8CQ34293614-42976392-A1A2-427C-B750-EA5A162C773AQ34328457-A60EBEE2-FC5B-4C2A-8391-2CF96E7F2CCBQ34353635-7D8869F0-30CC-4F63-90BF-08B951FCA8C7Q34812028-CCB2AF01-7168-476C-936E-45410904A894Q34898366-09F3495A-7A85-487C-A107-45FC0A41F36BQ35021619-D241DF16-DB3C-4750-9F3E-6D446582FD7FQ35040857-6017C887-3A7C-4194-AF8C-DCDF4E3812F6Q35050399-A72F56DD-88CA-4C59-9536-72E606A252D1Q35212837-2402183F-6833-4DD9-9CDA-58BC89A80253Q35681508-92C06D79-E15F-41AB-A799-A67506AC7F59Q35900294-E796611E-30CC-42E3-B60A-D67DD5EE9356Q36090223-426BB2A9-E2B8-4CED-BEE6-488C6A3F9AC4Q36239661-5FF62A11-B77E-4F25-877A-03EDD47C3270Q36265772-53C2B744-C491-44EA-866F-06D5231E63F4Q36388529-4BFE33E2-0699-413D-B4CD-559702685EE7Q36399108-2DFDA3A4-C5E1-4275-BDF3-0AD5488AAA8EQ36517706-9841B64E-ADBF-44A2-A1F7-451F3FB09766Q36624402-2048204D-AA9D-4D55-8AA5-C61AB3A983CEQ36665335-56C82682-5B9D-492D-90EF-ED5B361D5EF2Q37086013-3D040EAB-C109-474A-80D5-9759D722E9C7Q37533657-60514568-9F63-4846-9748-CEC9CC7D6205Q37564361-92BDDDC5-E845-49EB-AE9A-68FDF6FCF2B4Q37759033-47F5F973-2DCF-4E09-9A32-560BCE0A8B15Q37773276-4C1F2F87-72A4-4679-9F02-5B7BF37E728AQ37849976-C9EE77D4-E64F-417B-83F6-55B436CC6135
P2860
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Phase I study in melanoma pati ...... ematopoietic progenitor cells.
@en
type
label
Phase I study in melanoma pati ...... ematopoietic progenitor cells.
@en
prefLabel
Phase I study in melanoma pati ...... ematopoietic progenitor cells.
@en
P2093
P1476
Phase I study in melanoma pati ...... ematopoietic progenitor cells.
@en
P2093
A Lindemann
A Mackensen
G C Spagnoli
V Cerundolo
P304
P356
10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T
P577
2000-05-01T00:00:00Z